<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-121832</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Calcium nephrolithiasis induced by topiramate</dc:title>
<dc:description xml:lang="en">Topiramate is an approved drug to treat seizures, but its indications have been extended to other diseases of the nervous system and as an adjuvant to chronic pain. We present four cases of topiramate-induced nephrolithiasis from 2006-2012 in women whose treatment was prescribed for pain control and as a mood stabilizer at doses of 250-300 mg/day. In two cases, the lithiasis was caused by calcium phosphate (apatite) and in the other two cases by oxalate and calcium phosphate. The most common metabolic alteration was an alkaline pH, followed by hypocitraturia. The drug was discontinued in two patients; it was reduced in one and was maintained in the fourth. An increase in fluid and potassium citrate intake was prescribed. In patients starting treatment with topiramate, an adequate control and prevention of nephrolithiasis should be performed due to the risk of mixed tubular acidosis and hypocitraturia (AU)</dc:description>
<dc:creator>Arrabal-Polo, Miguel Ángel</dc:creator>
<dc:creator>Arrabal-Martín, Miguel</dc:creator>
<dc:creator>Merino-Salas, Sergio</dc:creator>
<dc:creator>Cano-García, María del Carmen</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El topiramato es un fármaco aprobado para el tratamiento de crisis convulsivas, pero cuya indicación se ha extendido a otras patologías del sistema nervioso y como adyuvante del dolor crónico. En el periodo de 2006-2012 presentamos 4 casos de litiasis renal inducida por topiramato en mujeres cuyo tratamiento fue prescrito para control del dolor y como estabilizador del ánimo en dosis entre 250-300 mg/día. En dos casos la litiasis fue de fosfato cálcico (apatita) y otros dos casos de litiasis de oxalato y fosfato cálcico. La alteración metabólica más frecuente fue pH urinario alcalino seguido de hipocitraturia. Se retiró el fármaco en 2 pacientes, en 1 se redujo la dosis y en otro se mantuvo. Se indicó aumento de ingesta hídrica y citrato potásico. En pacientes que inician tratamiento con topiramato debe realizarse un control y profilaxis adecuada de litiasis renal por riesgo de acidosis tubular mixta e hipocitraturia (AU)</dc:description>
<dc:source>Arch Esp Urol;67(3): 284-287, abr. 2014. tab</dc:source>
<dc:identifier>ibc-121832</dc:identifier>
<dc:title xml:lang="es">Nefrolitiasis cálcica inducida por topiramato</dc:title>
<dc:subject>^d10333^s22057</dc:subject>
<dc:subject>^d52124^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d934^s22020</dc:subject>
<dc:subject>^d54692^s22045</dc:subject>
<dc:subject>^d32980^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201404</dc:date>
</metadata>
</record>
</ibecs-document>
